Trial Profile

An investigator-initiated, individually randomized, open-label trial to assess the efficacy and safety of oral favipiravir in adolescents and adults (aged ≥16 years) admitted to hospital with asymptomatic to mild COVID-19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2022 Results (n=66)deriving specimens from COVID-19 patients who received 10 days of favipiravir in this study for assessing baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients, published in the International Journal of Infectious Diseases
29 Sep 2020 New trial record
12 Sep 2020 Results published in the Antimicrobial Agents and Chemotherapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com